Olema Pharmaceuticals Inc (OLMA)

$12.09

-0.55

(-4.35%)▲

Market is closed - opens 7 PM, 21 Sep 2023

Performance

  • $12.07
    $12.96
    $12.09
    downward going graph

    0.17%

    Downside

    Day's Volatility :6.87%

    Upside

    6.71%

    downward going graph
  • $2.19
    $13.50
    $12.09
    downward going graph

    81.89%

    Downside

    52 Weeks Volatility :83.78%

    Upside

    10.44%

    downward going graph

Returns

PeriodOlema Pharmaceuticals IncSector (Health Care)Index (Russel 2000)
3 Months
43.93%
0.0%
0.0%
6 Months
247.25%
3.0%
-0.5%
1 Year
325.59%
7.2%
0.4%
3 Years
-74.2%
27.5%
19.1%

Highlights

Market Capitalization
467.3M
Book Value
$3.93
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-2.53
Wall Street Target Price
20.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-29.67%
Return On Equity TTM
-48.9%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-101.3M
Diluted Eps TTM
-2.53
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.34
EPS Estimate Next Year
-2.51
EPS Estimate Current Quarter
-0.73
EPS Estimate Next Quarter
-0.72

Analyst Recommendation

Buy
    92%Buy
    7%Hold
    0
    0%Sell
Based on 14 Wall street analysts offering stock ratings for Olema Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
13
13
12
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 65.43%

Current $12.09
Target $20.00

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Olema Pharmaceuticals Inc
Olema Pharmaceuticals Inc
35.33%
247.25%
325.59%
-74.2%
-74.2%
Moderna, Inc.
Moderna, Inc.
-3.91%
-29.82%
-15.12%
54.11%
473.87%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.9%
10.13%
22.22%
50.58%
114.4%
Novo Nordisk A/s
Novo Nordisk A/s
2.45%
29.29%
91.93%
176.03%
299.56%
Seagen, Inc.
Seagen, Inc.
7.77%
4.2%
47.16%
16.48%
167.89%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
2.14%
18.37%
27.77%
35.7%
98.94%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Olema Pharmaceuticals Inc
Olema Pharmaceuticals Inc
NA
NA
NA
-2.34
-0.49
-0.3
0.0
3.93
Moderna, Inc.
Moderna, Inc.
35.66
35.66
0.0
-3.66
0.07
0.01
0.0
44.49
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
22.39
22.39
9.01
41.82
0.19
0.1
0.0
225.94
Novo Nordisk A/s
Novo Nordisk A/s
43.6
43.6
2.03
3.3
0.82
0.22
0.01
2.52
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-3.47
-0.26
-0.13
0.0
13.96
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
27.75
27.75
0.41
14.71
0.25
0.16
0.0
60.01
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Olema Pharmaceuticals Inc
Olema Pharmaceuticals Inc
Buy
$467.3M
-74.2%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$39.6B
473.87%
35.66
11.33%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$90.8B
114.4%
22.39
33.93%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$834.9B
299.56%
43.6
33.4%
Seagen, Inc.
Seagen, Inc.
Hold
$38.9B
167.89%
NA
-33.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$92.5B
98.94%
27.75
35.4%

Institutional Holdings

  • Bvf Inc

    18.41%

  • Logos Global Management LP

    9.05%

  • Paradigm Biocapital Advisors LP

    9.02%

  • Cormorant Asset Management, LLC

    7.45%

  • BlackRock Inc

    5.64%

  • Vanguard Group Inc

    4.05%

Corporate Announcements

  • Olema Pharmaceuticals Inc Earnings

    Olema Pharmaceuticals Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

olema oncology is a biopharmaceutical company developing innovative targeted therapies for women’s cancers. our lead program, op-1250, a potential best-in-class complete estrogen receptor antagonist (ceran), is in development to treat estrogen receptor-positive (er+), human epidermal growth factor receptor 2-negative (her2-) breast cancer. olema recently initiated a phase 1/2 dose-escalation and expansion clinical trial of op-1250. we are supported in our mission by experienced and accomplished scientists and board members, leading healthcare investors and some of the most innovative pharma companies. for more information about the company please visit www.olema.com.

Organization
Olema Pharmaceuticals Inc
Employees
67
CEO
Dr. Sean P. Bohen M.D., Ph.D.
Industry
Health Technology

Discover More

FAQs